Literature DB >> 8992938

"Sensitivity" and "specificity" reconsidered: the meaning of these terms in analytical and diagnostic settings.

A J Saah1, D R Hoover.   

Abstract

Imprecise usage of the terms "sensitivity" and "specificity" produces confusion in the diagnostic use of sophisticated laboratory test results. "Analytical sensitivity" represents the smallest amount of substance in a sample that can accurately be measured by an assay. "Analytical specificity" refers to the ability of an assay to measure on particular organism or substance, rather than others, in a sample. An assay's analytical sensitivity and analytical specificity are distinct from that assay's clinical diagnostic sensitivity and diagnostic specificity. "Diagnostic sensitivity" is the percentage of persons who have a given disorder who are identified by the assay as positive for the disorder. High analytical sensitivity does not guarantee acceptable diagnostic sensitivity. "Diagnostic specificity" is the percentage of persons who do not have a given condition who are identified by the assay as negative for the condition. False-positive reactions occur because of sample contamination and diminish the diagnostic specificity of the assay. The terms "sensitivity" and "specificity" should be used with the requisite adjectives because the "diagnostic" and the "analytical" meanings of these terms are very different.

Entities:  

Mesh:

Year:  1997        PMID: 8992938     DOI: 10.7326/0003-4819-126-1-199701010-00026

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  55 in total

1.  HIV load testing with small samples of whole blood.

Authors:  Katrin Steinmetzer; Thomas Seidel; Andreas Stallmach; Eugen Ermantraut
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

Review 2.  Validation of laboratory-developed molecular assays for infectious diseases.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Breathing new life into pneumonia diagnostics.

Authors:  David R Murdoch; Katherine L O'Brien; J Anthony G Scott; Ruth A Karron; Niranjan Bhat; Amanda J Driscoll; Maria Deloria Knoll; Orin S Levine
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

4.  Strategies for Optimizing the Diagnostic Predictive Value of Clostridium difficile Molecular Diagnostics.

Authors:  Larry K Kociolek
Journal:  J Clin Microbiol       Date:  2017-03-08       Impact factor: 5.948

Review 5.  Revisiting the Biological Variability of Cardiac Troponin: Implications for Clinical Practice.

Authors:  Nick S R Lan; Damon A Bell
Journal:  Clin Biochem Rev       Date:  2019-11

6.  Outcome of diagnostic tests using samples from patients with culture-proven human monocytic ehrlichiosis: implications for surveillance.

Authors:  J E Childs; J W Sumner; W L Nicholson; R F Massung; S M Standaert; C D Paddock
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

7.  An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis.

Authors:  W L Nicholson; J A Comer; J W Sumner; C Gingrich-Baker; R T Coughlin; L A Magnarelli; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

8.  Is molecular xenomonitoring of mosquitoes for Dirofilaria repens suitable for dirofilariosis surveillance in endemic regions?

Authors:  Aleksander Masny; Rusłan Sałamatin; Wioletta Rozej-Bielicka; Elzbieta Golab
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

9.  Detection of ciguatoxin in fish tissue using sandwich ELISA and neuroblastoma cell bioassay.

Authors:  Cara Empey Campora; Jan Dierking; Clyde S Tamaru; Yoshitsugi Hokama; Douglas Vincent
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

10.  Novel Diagnosis of Lyme Disease: Potential for CAM Intervention.

Authors:  Aristo Vojdani; Frank Hebroni; Yaniv Raphael; Jonathan Erde; Bernard Raxlen
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.